Your Cart

Second Supplementary Prospectus

Second Supplementary Prospectus

Imagion Biosystems has announced a Secondary Supplementary Prospectus.

Read the Secondary Supplementary Prospectus.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.